Is NRXP or ESLA more profitable?

Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% Estrella Immunopharma N/A N/A -397.36%

Which has better earnings and valuation, ESLA or NGEN?

NervGen Pharma is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A NervGen Pharma N/A N/A N/A -$0.09 N/A

Is ESLA or NGEN more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% NervGen Pharma N/A N/A N/A

Do analysts rate ESLA or CUE?

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 1,042.86%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ESLA or CUE?

In the previous week, Cue Biopharma had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Estrella Immunopharma. Cue Biopharma's average media sentiment score of 1.00 beat Estrella Immunopharma's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cue Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ESLA or PEPG?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is ESLA or PEPG more profitable?

Estrella Immunopharma's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% PepGen N/A -59.89% -49.62%

Does the media prefer ESLA or PEPG?

In the previous week, PepGen had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Estrella Immunopharma. PepGen's average media sentiment score of 1.04 beat Estrella Immunopharma's score of 0.00 indicating that PepGen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PepGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ESLA or TLSA?

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 1,042.86%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Estrella Immunopharma is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, ESLA or TLSA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is ESLA or TLSA more profitable?

Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Tiziana Life Sciences N/A N/A N/A

Does the media favor ESLA or TLSA?

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 1 mentions for Estrella Immunopharma. Tiziana Life Sciences' average media sentiment score of 0.50 beat Estrella Immunopharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Estrella Immunopharma (ESLA) Competitors

$0.71 +0.01 (+1.86%)

As of 09:44 AM Eastern

Compare

ESLA vs. NRXP, NGEN, CUE, PEPG, and TLSA

Should you buy Estrella Immunopharma stock or one of its competitors? MarketBeat compares Estrella Immunopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Estrella Immunopharma include NRx Pharmaceuticals (NRXP), NervGen Pharma (NGEN), Cue Biopharma (CUE), PepGen (PEPG), and Tiziana Life Sciences (TLSA).

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

In the previous week, Estrella Immunopharma had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Estrella Immunopharma	Neutral

Estrella Immunopharma has lower revenue, but higher earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	95.44	-$28.62M	-$1.09	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A

NRx Pharmaceuticals currently has a consensus price target of $38.25, suggesting a potential upside of 1,080.56%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 1,042.86%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe NRx Pharmaceuticals is more favorable than Estrella Immunopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NRx Pharmaceuticals has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
Estrella Immunopharma	N/A	N/A	-397.36%

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Estrella Immunopharma on 8 of the 12 factors compared between the two stocks.

How does Estrella Immunopharma compare to NervGen Pharma?

Estrella Immunopharma (NASDAQ:ESLA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

0.4% of Estrella Immunopharma shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NervGen Pharma is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
NervGen Pharma	N/A	N/A	N/A	-$0.09	N/A

In the previous week, Estrella Immunopharma had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for NervGen Pharma. Estrella Immunopharma's average media sentiment score of 0.00 equaled NervGen Pharma'saverage media sentiment score.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
NervGen Pharma	Neutral

Estrella Immunopharma currently has a consensus price target of $8.00, suggesting a potential upside of 1,042.86%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 753.66%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than NervGen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
NervGen Pharma	N/A	N/A	N/A

Summary

NervGen Pharma beats Estrella Immunopharma on 6 of the 10 factors compared between the two stocks.

How does Estrella Immunopharma compare to Cue Biopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Cue Biopharma (NASDAQ:CUE) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Estrella Immunopharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Estrella Immunopharma's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 1,042.86%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Estrella Immunopharma has higher earnings, but lower revenue than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Cue Biopharma	$27.47M	4.11	-$26.60M	-$5.58	N/A

In the previous week, Cue Biopharma had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for Estrella Immunopharma. Cue Biopharma's average media sentiment score of 1.00 beat Estrella Immunopharma's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 14.6% of Cue Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Estrella Immunopharma beats Cue Biopharma on 8 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to PepGen?

Estrella Immunopharma (NASDAQ:ESLA) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Estrella Immunopharma's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
PepGen	N/A	-59.89%	-49.62%

Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, PepGen has a beta of 1.89, suggesting that its share price is 89% more volatile than the broader market.

In the previous week, PepGen had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for PepGen and 1 mentions for Estrella Immunopharma. PepGen's average media sentiment score of 1.04 beat Estrella Immunopharma's score of 0.00 indicating that PepGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PepGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Estrella Immunopharma is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 58.0% of PepGen shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by insiders. Comparatively, 1.3% of PepGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,042.86%. PepGen has a consensus target price of $11.50, suggesting a potential upside of 511.70%. Given Estrella Immunopharma's higher probable upside, equities analysts clearly believe Estrella Immunopharma is more favorable than PepGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

PepGen beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Estrella Immunopharma (NASDAQ:ESLA) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Tiziana Life Sciences had 3 more articles in the media than Estrella Immunopharma. MarketBeat recorded 4 mentions for Tiziana Life Sciences and 1 mentions for Estrella Immunopharma. Tiziana Life Sciences' average media sentiment score of 0.50 beat Estrella Immunopharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

0.4% of Estrella Immunopharma shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Tiziana Life Sciences	N/A	N/A	N/A

Estrella Immunopharma presently has a consensus price target of $8.00, suggesting a potential upside of 1,042.86%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Estrella Immunopharma is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Estrella Immunopharma beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.71M	$3.55B	$6.86B	$12.43B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-2.06	7.29	280.73	24.99
Price / Sales	N/A	1,266.92	643.21	112.42
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-2.59	16.69	10.94	6.21
Net Income	-$13.06M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-6.48%	0.24%	0.78%	1.28%
1 Month Performance	-28.75%	-7.52%	-4.20%	-3.62%
1 Year Performance	-15.49%	47.22%	61.51%	18.37%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	1.6993 of 5 stars	$0.71 +1.9%	$8.00 +1,022.0%	-19.0%	$30.21M	N/A	N/A	N/A	Gap Up
NRXP NRx Pharmaceuticals	1.575 of 5 stars	$3.23 -8.8%	$38.25 +1,084.2%	+25.1%	$128.25M	$1.23M	N/A	2	Positive News
NGEN NervGen Pharma	1.526 of 5 stars	$1.59 -1.2%	$14.00 +780.5%	N/A	$128.20M	N/A	N/A	N/A	Positive News
CUE Cue Biopharma	0.4761 of 5 stars	$28.01 -7.4%	N/A	-96.0%	$127.06M	$27.47M	N/A	60	News Coverage
PEPG PepGen	3.0825 of 5 stars	$1.71 -6.6%	$11.50 +572.5%	+42.4%	$126.58M	N/A	N/A	30	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. NRXP, NGEN, CUE, PEPG, and TLSA

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

Summary

How does Estrella Immunopharma compare to NervGen Pharma?

Summary

How does Estrella Immunopharma compare to Cue Biopharma?

Summary

How does Estrella Immunopharma compare to PepGen?

Summary

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. NRXP, NGEN, CUE, PEPG, and TLSA

How does Estrella Immunopharma compare to NRx Pharmaceuticals?

Does the media prefer NRXP or ESLA?

Which has higher earnings & valuation, NRXP or ESLA?

Do analysts prefer NRXP or ESLA?

Which has more risk and volatility, NRXP or ESLA?

Is NRXP or ESLA more profitable?

Do institutionals & insiders have more ownership in NRXP or ESLA?

Summary

How does Estrella Immunopharma compare to NervGen Pharma?

Do institutionals & insiders have more ownership in ESLA or NGEN?

Which has better earnings and valuation, ESLA or NGEN?

Does the media prefer ESLA or NGEN?

Do analysts rate ESLA or NGEN?

Is ESLA or NGEN more profitable?

Summary

How does Estrella Immunopharma compare to Cue Biopharma?

Is ESLA or CUE more profitable?

Do analysts rate ESLA or CUE?

Which has higher valuation and earnings, ESLA or CUE?

Does the media favor ESLA or CUE?

Which has more risk and volatility, ESLA or CUE?

Do insiders & institutionals have more ownership in ESLA or CUE?

Summary

How does Estrella Immunopharma compare to PepGen?

Is ESLA or PEPG more profitable?

Which has more risk and volatility, ESLA or PEPG?

Does the media prefer ESLA or PEPG?

Which has higher earnings and valuation, ESLA or PEPG?

Do insiders and institutionals have more ownership in ESLA or PEPG?

Do analysts recommend ESLA or PEPG?

Summary

How does Estrella Immunopharma compare to Tiziana Life Sciences?

Does the media favor ESLA or TLSA?

Which has stronger earnings and valuation, ESLA or TLSA?

Which has more volatility & risk, ESLA or TLSA?

Do institutionals & insiders have more ownership in ESLA or TLSA?

Is ESLA or TLSA more profitable?

Do analysts rate ESLA or TLSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools